Last reviewed · How we verify
NCT05554068
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Phase 2 trial testing Shingrix in Shingles in 100 participants. Currently enrolling.
7 March 2025
Quick facts
| Lead sponsor | Loyola University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 7 March 2023 |
| Primary completion | 7 March 2025 |
| Estimated completion | 1 November 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Shingrix (shingrix) — full drug profile →
Conditions studied
- Shingles — all drugs for Shingles →
Sponsor
Loyola University
Who can join
Eligibility, any sex, with Shingles. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05554068
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Shingrix
Trials testing the same drug.
- NCT07205796 — A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) i · Phase 2 · not yet recruiting
- NCT06763783 — Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases · Phase 4 · enrolling by invitation
- NCT06409494 — Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years · Phase 1 · active not recruiting
- NCT06375512 — A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Health · Phase 1 · completed
- NCT05991427 — A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years · Phase 1 · completed
Other recruiting trials for Shingles
Currently open trials in the same condition.
- NCT05596526 — Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients · Phase 4 · recruiting
- NCT05304351 — Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older · Phase 2 · active not recruiting
Other Loyola University trials
Trials by the same sponsor.
- NCT07517224 — Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer · NA · not yet recruiting
- NCT06486714 — Mechanical Alignment Versus Kinematic Alignment Total Knee Arthroplasty · NA · not yet recruiting
- NCT07216664 — Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants · NA · recruiting
- NCT07226505 — Effects of Core Strengthening Exercises for Treating TMD · NA · not yet recruiting
- NCT06525701 — Surgeon Core-strengthening Program as a Modifier for Exertion Associated With Vaginal Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05554068 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Loyola University
- Last refreshed: 8 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05554068.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing